Impax to divest 10 products amid acquisition by Amneal
30-04-2018
albinaglisic / Shutterstock.com
Pharmaceutical company Impax Laboratories engaged in illegal pay-for-delay settlements to stop a generic version of one of Endo Pharmaceutical's medications from entering the market, the US Federal Trade Commission has ruled.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Impax, US Federal Trade Commission, Endo Pharmaceuticals, Opana, oxymorphone
